Anonymous10 days ago
A genetically distinct SARS-CoV-2 variant called BA.3.2, first identified in South Africa in November 2024, has been detected in wastewater samples from 29 U.S. states and in 29 clinical patient specimens as of mid-March 2026. While laboratory studies show BA.3.2 can evade antibodies generated by current vaccines, its prevalence remains below 1% of U.S. sequences, clinical severity data is extremely limited, and overall COVID activity is declining nationally—raising the question of whether this variant represents a genuine public health threat or routine viral evolution under heightened surveillance.